- Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK
- Dr. Reddy’s Q4 & Full Year FY24 Financial Results
- Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.
- Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
Key statistics
As of last trade Dr Reddy's Laboratories Ltd (RDY:NYQ) traded at 69.58, -10.47% below its 52-week high of 77.72, set on Feb 23, 2024.
52-week range
Open | 69.60 |
---|---|
High | 69.85 |
Low | 69.11 |
Bid | 69.56 |
Offer | 69.61 |
Previous close | 69.61 |
Average volume | 294.14k |
---|---|
Shares outstanding | 166.53m |
Free float | 166.00m |
P/E (TTM) | 17.35 |
Market cap | 11.80bn USD |
EPS (TTM) | 4.01 USD |
Annual div (ADY) | 0.4792 USD |
---|---|
Annual div yield (ADY) | 0.69% |
Div ex-date | Jul 28 2023 |
Div pay-date | Aug 11 2023 |
Data delayed at least 15 minutes, as of May 24 2024 19:49 BST.
More ▼